References
- Lippman S M., Shimm D S., Meyskens F L., Jr. Nonsurgical treatment for skin cancer: retinoids and alpha-interferon. J Dermatol Surg Oncol 1988; 14: 862–7
- Bunn P A., Ihde D C., Foon K A. The role of recombinant Interferon alpha 2a in the therapy of cutaneous T cell lymphomas. Cancer 1985; 57: 1689–95
- Vonderheid E C., Thompson R, Smiles K A., et al. Recombinant interferon alpha-2b in plaque phase mycosis fungoides: intralesional and low dose intramuscular therapy. Arch Dermatol 1987; 123: 757–63
- Holloway K B., Flowers F P., Ramos-Caro F A. Therapeutic alternatives in cutaneous T-cell lymphoma. J Am Acad Dermatol 1992; 27: 367–78
- Kirkwood J M., Ernstoff M S. Role of interferons in the therapy of melanoma. J Invest Dermatol 1990; 95: 180–5
- McLeod G R., Thompson D B., Hersey P. Clinical evaluation of interferons in malignant melanoma. J Invest Dermatol 1990; 95: 185–92
- Volberding P A., Mitsuyasu R T., Golando J P., et al. Treatment of Kaposi's sarcoma with interferon alpha-2b (Intron A). Cancer 1987; 59: 620–5
- Peris K, La Rosa F, Cerroni L, et al. Terapia dei linfomi cutanei. Malattie linfoproliferative cutanee e sistemiche. Firma Serviee, Genova 1992; 285, Scuola Internazionale di Oncologia e Medicina Sperimentale
- Cerroni L, Peris K, Torlone G, . Use of recombinant interferon alpha-2a in the treatment of cutaneous lymphomas of T- and B-cell lineage. Basic mechanism of physiologic and aberrant lymphoproliferations of the skin, W C. Lambert, et al. Plenum Press, New York 1994; 545–51
- Zenone T, Catimel G, Barbet N, et al. Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a. Eur J Cancer 1994; 30: 246–8
- Shuttleworth D, Marks R. A comparison of the effects of intralesional interferon alpha-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease. J Dermatol Treat 1989; 1: 65–8
- Tucher S B. Interferon-alpha treatment of basal cell and squamous cell skin tumor. Cancer Bull 1993; 45: 270–5
- Grobb J J., Collet A M., Munoz M H., et al. Treatment of large basal cell carcinomas with intralesional interferon alpha-2a. Lancet 1988; 1: 878–9
- Green way H T., Cornell R C., Tanner D J., et al. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 1986; 15: 437–43
- Chimenti S, Peris K, Cristofaro D S., et al. Use of recombinant alpha 2b Interferon in the treatment of basal cell carcinoma. Dermatology 1995; 190: 214–217
- Wickramasinghe L, Hindson T C., Wacks H. Treatment of neoplastic skin lesions with intralesional interferon. J Am Acad Dermatol 1989; 20: 71–4
- Edwards L, Berman B, Rapini R P., et al. Treatment of cutaneous squamous cell carcinoma by intralesional interferon alpha-2b therapy. Arch Dermatol 1992; 128: 1486–9
- Gresser I. How does Interferon inhibit tumor growth?. Interferon 1985; 6: 93–123
- Rossi G B. Interferons and cell differentiation. Interferon 1985; 6: 31–62
- Baron S, Tyring S K., Fleishmann W R., Jr. The interferons: mechanisms of action and clinical application. JAMA 1991; 266: 1375–83
- Herberman R B., Ortalddjdsko J R., Mantovani A. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol 1982; 67: 160–7
- Mozzanica N, Cattaneo A, Boneschi W, et al. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha-2 interferon. Arch Dermatol Res 1990; 282: 311–17
- Buechner S A. Intralesional alpha-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. J Am Acad Dermatol 1991; 24: 731–4